Introduction: In the first half of 2025, 49 merger and acquisition (M&A) deals with a total value of 12.7 billion yuan outlined a clear trajectory of the industry's transformation from "unbridled growth" to "meticulous cultivation."
While 3SBio's $6 billion overseas transaction shocked the world, another battlefield in China's domestic pharmaceutical industry was quietly heating up-in the first half of 2025, 49 M&A deals with a total value of 12.7 billion yuan sketched the industry's distinct shift from "unbridled growth" to "meticulous cultivation."
Stable Volume, Declining Prices
The 2025 pharmaceutical M&A market exuded a calmness starkly different from the overseas expansion boom. Data shows that the number of M&A deals in the first half remained the same as in 2024, but the transaction value halved year-on-year. This "stable volume with declining prices" characteristic signals a return to rationality in the industry-moving away from "sky-high acquisitions" worth billions, companies now prefer to fill strategic gaps through "small, quick steps."
From the perspective of transaction targets, three key themes stand out:
Reevaluation of Traditional Chinese Medicine (TCM) Value: Shanghai Pharmaceuticals increased its stake in Shanghai Hutchison Pharmaceuticals to 60% for 995 million yuan, not only securing Shexiang Baoxin Pill-a TCM blockbuster with annual sales exceeding 2 billion yuan-but also acquiring the mature overseas pathway of Daning Tablets in Canada. This marks a shift for TCM enterprises from "resource competition" to "acquiring international capabilities," providing a new paradigm for classic formulas.
Vertical Integration of Industrial Chains: OPM's 1.451 billion yuan acquisition of Pengli Bio integrated preclinical CRO services into its cell culture CDMO system, forming a "R&D-production" closed loop. This "upstream-downstream interlocking M&A" enabled enterprises to improve process efficiency by over 20% amid the high costs of biopharmaceutical R&D.
Scramble for Scarce Qualifications: Shanghai RAAS's 4.2 billion yuan cash acquisition of Nanyue Bio is a textbook case-the latter holds Hunan Province's only blood product production qualification, combined with 9 plasma stations and a designed capacity of 500 tons, forming a "qualification + capacity" dual moat. After the acquisition, Shanghai RAAS's total plasma stations jumped to 53, and its 1,778-ton plasma collection volume will secure its position in the industry's first tier.
Geographically, state-owned enterprises have made notable moves. Shanghai, Beijing, Guangzhou, and other cities, relying on multi-billion-yuan industrial M&A funds, have promoted cross-regional integration of local leaders. For example, Shanghai Pharmaceuticals' stake increase received special support from the Shanghai Biomedical Industry Fund, a "capital + industry" synergy model reshaping regional pharmaceutical industry landscapes.
Driving Logic
Before the effects of the 2024 "Six M&A Guidelines" faded, local governments launched multi-billion-yuan funds in 2025. The Shanghai 10 billion yuan biomedical M&A fund, Beijing 50 billion yuan medical and health industry fund, and Guangzhou 10 billion yuan listed company development fund formed a nationwide M&A capital network. Targeted policy efforts are breaking down "approval barriers," "payment bottlenecks," and "valuation deadlocks" that plagued past M&As.
The China Securities Regulatory Commission (CSRC) explicitly stated at the 2025 Lujiazui Forum its "support for listed companies to achieve innovative transformation through M&A and restructuring," shortening the review cycle for pharmaceutical industry M&As to 30 working days-a 40% reduction from 2024. This "regulatory empowerment" directly facilitated rapid closures such as Sunho's acquisition of Langyan Life, which took only 58 days from agreement signing to completion, setting an industry record.
Market-driven forces are even stronger. Multinational pharmaceutical companies' "patent cliff" pressures have transmitted along the industrial chain, forcing domestic enterprises to seize niche tracks through M&As. AstraZeneca's $160 million acquisition of FibroGen the exclusive position of Roxadustat in treating anemia in chronic kidney disease-the world's first HIF-PH inhibitor, with nearly 2 billion yuan in hospital sales in 2023, directly filling AstraZeneca's pipeline gap in nephrology.
Survival anxiety among local enterprises has further spurred M&A demand. Under the normalization of centralized procurement, profit margins for small and medium-sized pharmaceutical companies have continued to shrink; in 2024, 32 listed pharmaceutical companies saw their non-net profits decline by over 50% year-on-year. Shengxiang Bio's 800 million yuan premium acquisition of Zhongshan Haiji is a typical "survival-driven expansion"-by integrating growth hormone product lines into its diagnostic reagent system, it opened a second growth curve, with Zhongshan Haiji's 105 million yuan net profit in 2024 becoming a key support.
Model Innovation
The 2025 M&A market is quietly transforming from "buying products" to "buying ecosystems." The success of the NewCo model in overseas expansion is being replicated in domestic M&As, spawning more flexible value distribution mechanisms.
Connaught's layout in the CD38 monoclonal antibody field is exemplary-by taking a stake in Timberlyne Therapeutics and licensing overseas rights, it not only received a $30 million down payment but also locked in long-term returns with a 25.79% equity stake. This "technology licensing + equity binding" model is being adopted by Sunho: in acquiring Langyan Life, Sunho not only paid cash but also agreed to supplement with revenue sharing from self-developed pipelines, turning M&A from a "one-time transaction" into "long-term symbiosis."
More noteworthy is "industrial chain puzzle-style M&A." After acquiring Pengli Bio, OPM packaged cell culture reagents with preclinical CRO services, launching a one-stop solution "from target validation to IND application." This "1+1>2" synergy confirms the feasibility of Danaher's "M&A-integration-efficiency improvement" model in China.
Compared with the M&A paths of international giants, domestic enterprises are forging differentiated routes. Thermo Fisher became a global life sciences giant through M&As by achieving "technological platform monopoly"; Chinese enterprises, however, prefer "niche market positioning"-Shanghai RAAS focuses on blood product plasma station resources, and Kelun-Biotech specializes in ADC technology. This focused M&A approach makes it easier to build competitiveness in specific fields.
Hidden Concerns and Breakthroughs
Behind the 12.7 billion yuan total transaction value lie three deep-seated challenges that the industry must address with clear awareness.
Imbalances in value evaluation systems are particularly prominent. Domestic enterprises still lack proficiency in assessing asset value; pricing logic for early-stage technical assets is often limited to short-term revenue expectations, failing to fully consider global market potential and technological iteration space. This leads to both undervaluation of high-quality assets and bubble-driven pricing. Such professional gaps leave domestic M&As in a weak position in global value chain distribution.
Hidden geopolitical risks cannot be ignored. In cross-border M&As, issues such as intellectual property ownership and restrictions on technology transfer are increasingly prominent. Industrial protection policies in some regions may hinder post-M&A technological synergy. Especially in strategic fields like innovative drugs and high-end medical devices, intertwined technical barriers and geopolitical games increase uncertainties in cross-border integration.
Widespread inadequacy in integration capabilities is the biggest bottleneck. Most enterprises remain stuck in the mindset that "acquisition equals completion," lacking systematic plans for post-M&A cultural integration, process reengineering, and resource synergy. Poor alignment between technical and management teams, and disconnects between R&D pipelines and market channels, often prevent the release of target asset value and even drag down the acquirer's original business.
The key to breaking through lies in building a "three-dimensional evaluation framework": - Technically, focus on global scarcity and clinical value, with FIC (First-in-Class) potential and platform technologies as core indicators, breaking free from reliance on follow-up innovation. - Market-wise, establish a dual-track calculation model of "domestic medical insurance + international commercialization," balancing short-term gains and long-term. - Organizationally, include team stability in core clauses, ensuring key resources remain through equity incentives and R&D synergy mechanisms. Only then can M&A evolve from simple asset accumulation to a true engine of value creation.
Conclusion
While 73 oral presentations by Chinese pharmaceutical companies at the ASCO annual meeting shocked the world, the 12.7 billion yuan in domestic M&A transactions are driving a more profound transformation. This is not mere scale expansion but an "industry surgery" using M&A as a scalpel-removing inefficient capacity, bridging technical gaps, and reshaping value chains.
Policy dividends will continue to flow: the third GEM listing standard opens financing channels for innovative pharmaceutical companies; multi-billion-yuan industrial funds provide M&A ammunition; and multinational pharmaceutical companies' "patent cliffs" will release more cooperation opportunities. Dongwu Securities predicts that China's pharmaceutical market will exceed 2 trillion yuan by 2030, with M&A integration as a key driver. 30. As Shanghai Pharmaceuticals stated in its strategic declaration when acquiring Hutchison Pharmaceuticals: "We are not just acquiring a drug, but a complete methodology for TCM internationalization." The 49 deals and 12.7 billion yuan in 2025 will ultimately mark China's pharmaceutical industry's milestone shift from the "scale era" to the "value era."
References:
1. "2025 H1 Pharmaceutical M&A: 'Rising Volume and Prices'-High-Frequency, Small-Scale Transactions Prevail with Policy Support," Chenyu Matou, July 11, 2025
2. Dongwu Securities: "Outlook Report on China's Innovative Pharmaceutical Industry by 2030"
3. China Insights Consultancy: "White Paper on Pharmaceutical Industry M&A Integration" (2025 Edition)
4. M&A announcements and investor relations records of listed pharmaceutical companies
While 3SBio's $6 billion overseas transaction shocked the world, another battlefield in China's domestic pharmaceutical industry was quietly heating up-in the first half of 2025, 49 M&A deals with a total value of 12.7 billion yuan sketched the industry's distinct shift from "unbridled growth" to "meticulous cultivation."
Stable Volume, Declining Prices
The 2025 pharmaceutical M&A market exuded a calmness starkly different from the overseas expansion boom. Data shows that the number of M&A deals in the first half remained the same as in 2024, but the transaction value halved year-on-year. This "stable volume with declining prices" characteristic signals a return to rationality in the industry-moving away from "sky-high acquisitions" worth billions, companies now prefer to fill strategic gaps through "small, quick steps."
From the perspective of transaction targets, three key themes stand out:
Reevaluation of Traditional Chinese Medicine (TCM) Value: Shanghai Pharmaceuticals increased its stake in Shanghai Hutchison Pharmaceuticals to 60% for 995 million yuan, not only securing Shexiang Baoxin Pill-a TCM blockbuster with annual sales exceeding 2 billion yuan-but also acquiring the mature overseas pathway of Daning Tablets in Canada. This marks a shift for TCM enterprises from "resource competition" to "acquiring international capabilities," providing a new paradigm for classic formulas.
Vertical Integration of Industrial Chains: OPM's 1.451 billion yuan acquisition of Pengli Bio integrated preclinical CRO services into its cell culture CDMO system, forming a "R&D-production" closed loop. This "upstream-downstream interlocking M&A" enabled enterprises to improve process efficiency by over 20% amid the high costs of biopharmaceutical R&D.
Scramble for Scarce Qualifications: Shanghai RAAS's 4.2 billion yuan cash acquisition of Nanyue Bio is a textbook case-the latter holds Hunan Province's only blood product production qualification, combined with 9 plasma stations and a designed capacity of 500 tons, forming a "qualification + capacity" dual moat. After the acquisition, Shanghai RAAS's total plasma stations jumped to 53, and its 1,778-ton plasma collection volume will secure its position in the industry's first tier.
Geographically, state-owned enterprises have made notable moves. Shanghai, Beijing, Guangzhou, and other cities, relying on multi-billion-yuan industrial M&A funds, have promoted cross-regional integration of local leaders. For example, Shanghai Pharmaceuticals' stake increase received special support from the Shanghai Biomedical Industry Fund, a "capital + industry" synergy model reshaping regional pharmaceutical industry landscapes.
Driving Logic
Before the effects of the 2024 "Six M&A Guidelines" faded, local governments launched multi-billion-yuan funds in 2025. The Shanghai 10 billion yuan biomedical M&A fund, Beijing 50 billion yuan medical and health industry fund, and Guangzhou 10 billion yuan listed company development fund formed a nationwide M&A capital network. Targeted policy efforts are breaking down "approval barriers," "payment bottlenecks," and "valuation deadlocks" that plagued past M&As.
The China Securities Regulatory Commission (CSRC) explicitly stated at the 2025 Lujiazui Forum its "support for listed companies to achieve innovative transformation through M&A and restructuring," shortening the review cycle for pharmaceutical industry M&As to 30 working days-a 40% reduction from 2024. This "regulatory empowerment" directly facilitated rapid closures such as Sunho's acquisition of Langyan Life, which took only 58 days from agreement signing to completion, setting an industry record.
Market-driven forces are even stronger. Multinational pharmaceutical companies' "patent cliff" pressures have transmitted along the industrial chain, forcing domestic enterprises to seize niche tracks through M&As. AstraZeneca's $160 million acquisition of FibroGen the exclusive position of Roxadustat in treating anemia in chronic kidney disease-the world's first HIF-PH inhibitor, with nearly 2 billion yuan in hospital sales in 2023, directly filling AstraZeneca's pipeline gap in nephrology.
Survival anxiety among local enterprises has further spurred M&A demand. Under the normalization of centralized procurement, profit margins for small and medium-sized pharmaceutical companies have continued to shrink; in 2024, 32 listed pharmaceutical companies saw their non-net profits decline by over 50% year-on-year. Shengxiang Bio's 800 million yuan premium acquisition of Zhongshan Haiji is a typical "survival-driven expansion"-by integrating growth hormone product lines into its diagnostic reagent system, it opened a second growth curve, with Zhongshan Haiji's 105 million yuan net profit in 2024 becoming a key support.
Model Innovation
The 2025 M&A market is quietly transforming from "buying products" to "buying ecosystems." The success of the NewCo model in overseas expansion is being replicated in domestic M&As, spawning more flexible value distribution mechanisms.
Connaught's layout in the CD38 monoclonal antibody field is exemplary-by taking a stake in Timberlyne Therapeutics and licensing overseas rights, it not only received a $30 million down payment but also locked in long-term returns with a 25.79% equity stake. This "technology licensing + equity binding" model is being adopted by Sunho: in acquiring Langyan Life, Sunho not only paid cash but also agreed to supplement with revenue sharing from self-developed pipelines, turning M&A from a "one-time transaction" into "long-term symbiosis."
More noteworthy is "industrial chain puzzle-style M&A." After acquiring Pengli Bio, OPM packaged cell culture reagents with preclinical CRO services, launching a one-stop solution "from target validation to IND application." This "1+1>2" synergy confirms the feasibility of Danaher's "M&A-integration-efficiency improvement" model in China.
Compared with the M&A paths of international giants, domestic enterprises are forging differentiated routes. Thermo Fisher became a global life sciences giant through M&As by achieving "technological platform monopoly"; Chinese enterprises, however, prefer "niche market positioning"-Shanghai RAAS focuses on blood product plasma station resources, and Kelun-Biotech specializes in ADC technology. This focused M&A approach makes it easier to build competitiveness in specific fields.
Hidden Concerns and Breakthroughs
Behind the 12.7 billion yuan total transaction value lie three deep-seated challenges that the industry must address with clear awareness.
Imbalances in value evaluation systems are particularly prominent. Domestic enterprises still lack proficiency in assessing asset value; pricing logic for early-stage technical assets is often limited to short-term revenue expectations, failing to fully consider global market potential and technological iteration space. This leads to both undervaluation of high-quality assets and bubble-driven pricing. Such professional gaps leave domestic M&As in a weak position in global value chain distribution.
Hidden geopolitical risks cannot be ignored. In cross-border M&As, issues such as intellectual property ownership and restrictions on technology transfer are increasingly prominent. Industrial protection policies in some regions may hinder post-M&A technological synergy. Especially in strategic fields like innovative drugs and high-end medical devices, intertwined technical barriers and geopolitical games increase uncertainties in cross-border integration.
Widespread inadequacy in integration capabilities is the biggest bottleneck. Most enterprises remain stuck in the mindset that "acquisition equals completion," lacking systematic plans for post-M&A cultural integration, process reengineering, and resource synergy. Poor alignment between technical and management teams, and disconnects between R&D pipelines and market channels, often prevent the release of target asset value and even drag down the acquirer's original business.
The key to breaking through lies in building a "three-dimensional evaluation framework": - Technically, focus on global scarcity and clinical value, with FIC (First-in-Class) potential and platform technologies as core indicators, breaking free from reliance on follow-up innovation. - Market-wise, establish a dual-track calculation model of "domestic medical insurance + international commercialization," balancing short-term gains and long-term. - Organizationally, include team stability in core clauses, ensuring key resources remain through equity incentives and R&D synergy mechanisms. Only then can M&A evolve from simple asset accumulation to a true engine of value creation.
Conclusion
While 73 oral presentations by Chinese pharmaceutical companies at the ASCO annual meeting shocked the world, the 12.7 billion yuan in domestic M&A transactions are driving a more profound transformation. This is not mere scale expansion but an "industry surgery" using M&A as a scalpel-removing inefficient capacity, bridging technical gaps, and reshaping value chains.
Policy dividends will continue to flow: the third GEM listing standard opens financing channels for innovative pharmaceutical companies; multi-billion-yuan industrial funds provide M&A ammunition; and multinational pharmaceutical companies' "patent cliffs" will release more cooperation opportunities. Dongwu Securities predicts that China's pharmaceutical market will exceed 2 trillion yuan by 2030, with M&A integration as a key driver. 30. As Shanghai Pharmaceuticals stated in its strategic declaration when acquiring Hutchison Pharmaceuticals: "We are not just acquiring a drug, but a complete methodology for TCM internationalization." The 49 deals and 12.7 billion yuan in 2025 will ultimately mark China's pharmaceutical industry's milestone shift from the "scale era" to the "value era."
References:
1. "2025 H1 Pharmaceutical M&A: 'Rising Volume and Prices'-High-Frequency, Small-Scale Transactions Prevail with Policy Support," Chenyu Matou, July 11, 2025
2. Dongwu Securities: "Outlook Report on China's Innovative Pharmaceutical Industry by 2030"
3. China Insights Consultancy: "White Paper on Pharmaceutical Industry M&A Integration" (2025 Edition)
4. M&A announcements and investor relations records of listed pharmaceutical companies
